Table 4.

Estimated Cost-effectiveness of RSV Prophylaxis With Palivizumab or RSVIG Among Hypothetical Cohorts of Premature Infants*

GroupPalivizumabRSVIG
Cost per
Case Averted
Cost per
Life-year Saved
Number Needed
to Treat
Cost Per
Case Averted
Cost Per
Life-year Saved
Number Needed
to Treat
A12 00033 0007.425 00070 0008.5
B39 000110 0001769 000190 00020
C56 000160 0002396 000270 00026
D160 000440 00059260 000730 00067
E38 000110 0001767 000190 00019
F110 000300 00041180 000510 00047
G150 000430 00057250 000710 00065
H420 0001 200 000152690 0001 900 000170
  • * Costs are calculated from the societal perspective in 1995 US dollars. The net cost is the cost of intervention and hospitalization relative to no prophylaxis.